Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
Partnerships 14
BerGenBio Enters into Agreement with Merck 14
Licensing Agreements 15
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
Equity Offering 16
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA – Key Competitors 21
BerGenBio ASA – Key Employees 22
BerGenBio ASA – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 15, 2018: BerGenBio: Results for the First Quarter 2018 24
Aug 18, 2017: BerGenBio: Results for the Second Quarter and Half year 2017 25
May 23, 2017: BerGenBio: Results for the First Quarter 2017 26
Product News 28
12/14/2017: BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference 28
12/11/2017: BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting 29
11/17/2017: BerGenBio: Results for the Third Quarter 2017 30
11/01/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting 31
10/12/2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma 32
06/06/2017: BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 33
01/09/2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017 34
Clinical Trials 35
Jan 29, 2018: BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy 35
Jan 09, 2018: BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC 37
Jan 08, 2018: BerGenBio to present at Biotech Showcase 2018 38
Nov 14, 2017: BerGenBio Presents BGB324 and KEYTRUDA (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium 39
Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 40
Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer 41
Jul 26, 2017: BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer – World R&D Summit in Boston 42
Jun 26, 2017: BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA for Advanced Lung Cancer 43
May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 44
Other Significant Developments 45
Aug 21, 2018: BerGenBio: Results for the Second Quarter and First Half 2018 45
Feb 13, 2018: BerGenBio: Results for the Fourth Quarter and Full Year 2017 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
BerGenBio ASA, Pharmaceuticals & Healthcare, Key Facts 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Deals By Therapy Area, 2012 to YTD 2018 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Enters into Agreement with Merck 14
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 15
BerGenBio to Raise USD24 Million in Private Placement of Shares 16
BerGenBio Raises USD47 Million in IPO 17
BerGenBio Raises USD25 Million in Private Placement of Shares 18
BerGenBio Raises USD12 Million in Private Placement of Shares 19
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 20
BerGenBio ASA, Key Competitors 21
BerGenBio ASA, Key Employees 22
List of Figures
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9